EyePoint Q2 FY26 net loss widens to $94.47 million; revenue drops to $507,000

PUBT · 1d ago
EyePoint Q2 FY26 net loss widens to $94.47 million; revenue drops to $507,000
  • EyePoint posted Q2 net loss of USD 94.5 million, or USD 1.09 per share, widening from a loss of USD 59.4 million, or USD 0.85 per share.
  • Revenue fell to USD 0.5 million from USD 5.3 million, due to recognition of remaining deferred revenue tied to a 2023 YUTIQ license deal.
  • Operating expenses climbed to USD 97.9 million from USD 67.6 million, on higher DURAVYU Phase 3 trial spending and manufacturing scale-up.
  • Cash and investments totaled USD 180 million at June 30, down from USD 223 million at March 31; runway forecast into Q4 2027.
  • LUGANO Phase 3 wet AMD topline data expected in August 2026, with LUCIA slated for Q4 2026; COMO and CAPRI Phase 3 DME trials fully enrolled, with topline data expected in Q4 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. EyePoint Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608050700PRIMZONEFULLFEED9803794) on August 05, 2026, and is solely responsible for the information contained therein.